After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its Matrix-M vaccine adjuvant as a versatile, license-ready asset for other biopharma companies like Sanofi and Pfizer.
- Home |
- With Sanofi and Pfizer deals, Novavax bets on ‘amplification strategy’ to drive vaccines engine
With Sanofi and Pfizer deals, Novavax bets on ‘amplification strategy’ to drive vaccines engine
- April 3, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
